Abeona Therapeutics Inc. (0H7R.L) LSE
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Abeona Therapeutics Inc.
Address
6555 Carnegie Avenue
Cleveland, OH 44103
United States of America (the)
Phone
646 813 4701
Sector
Healthcare
Industry
Biotechnology
Employees
226
First IPO Date
January 29, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Vishwas Seshadri | President, Chief Executive Officer & Director | 1.52M | 1976 |
| Brendan O'Malley | Chief Legal Officer | 783,926 | 1969 |
| Joseph Walter Vazzano | Chief Financial Officer | 898,465 | 1984 |
| Megan Callan | Vice President & Head of Quality | 0 | N/A |
| Jon Voss | Vice President & Head of Quality | 0 | 1960 |
| Brian Kevany | Chief Technical & Scientific Officer | 0 | N/A |
| Gianine Esposito | Senior VP & Chief People Officer | 0 | N/A |
| James A. Gow | SVP, Head of Clinical Development & Medical Affairs | 0 | 1967 |
| Madhav Vasanthavada | Senior Vice President, Chief Commercial Officer & Head of Business Development | 0 | 1979 |
| Carl Denny | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Gregory Gin | Vice President of Investor Relations & Corporation Communications | 0 | N/A |
Description
Abeona Therapeutics Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of gene and cell therapies to combat critical, uncommon genetic illnesses. Their foremost developmental asset is EB-101, a personalized gene-corrected cell therapy that has progressed to Phase III clinical trials for the treatment of recessive dystrophic epidermolysis bullosa. The company's pipeline also encompasses several other programs: ABO-102, an adeno-associated virus (AAV)-based gene therapy designed for Sanfilippo syndrome type A; ABO-201, aimed at CLN3 disease; ABO-401, targeting cystic fibrosis; and ABO-50X, intended for genetic eye disorders. Additionally, Abeona actively advances AAV-based gene therapies through its proprietary AIM vector platform. Incorporated in 1974, the firm was initially named PlasmaTech Biopharmaceuticals, Inc. before officially adopting the name Abeona Therapeutics Inc. in June 2015. The company's corporate base is situated in New York, New York.
